Global Enzyme Replacement Therapy Revenue Is Nearly 7.39 Billion USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of enzyme replacement therapy developed rapidly, with an average growth rate of 13.55%. In 2017, global revenue of enzyme replacement therapy is nearly 7.39 billion USD.
The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017.
Enzyme replacement therapy is widely used in gaucher disease, fabry disease, mps disease, gastrointestinal diseases and other field. The most proportion of enzyme replacement therapy is for MPS Disease, and the revenue in 2017 is 1.73 billion USD.
North America is the largest consumption place, with a consumption market share nearly 70.77% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 21.25%.
Market competition is intense. Sanofi, Shire, BioMarin, AbbVie?, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.